Verona Pharma plc — Director's Dealing 2023

May 11, 2023

SEC Form 4/A — Form 4/A

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2023-05-01

Reporting Person: Rickard Kathleen A. (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-01	Ordinary Shares	M	15000	—	Acquired	2986136	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-01	Restricted Share Units	$	M	15000	Disposed	2029-03-29	Ordinary Shares (15000)	Direct

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs") (unless otherwise indicated), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Each Restricted Share Unit represented a contingent right to receive one (1) Ordinary Share of the Issuer (which may be represented by ADSs, each of which represents eight (8) Ordinary Shares of the Issuer) subject to certain time- and performance-based vesting criteria.

F3: Consists of (i) 1,743,488 Ordinary Shares underlying Restricted Share Units (each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer) (which are represented by 217,936 ADSs); and (ii) 1,242,648 Ordinary Shares underlying 155,331 ADSs.